Novavax Stock Surges on Strategic Pivot Toward Partnership Model

A dramatic strategic shift appears to be paying off for Novavax, as the biotech firm moves away from a high-risk direct sales approach toward a more sustainable partnership framework with established pharmaceutical giants. This fundamental change in business model is generating renewed optimism among investors for the previously struggling vaccine specialist.

The recent surge in Novavax’s share price can be directly attributed to its expanded collaboration with French pharmaceutical leader Sanofi. This agreement provides immediate financial relief through a $25 million milestone payment for the transfer of US marketing rights for the Nuvaxovid COVID-19 vaccine. More significantly, the deal marks Novavax’s transformation from a direct sales organization to a Read more...